Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Halts Gardasil Lobbying Efforts Following Discussions With ACIP, AAP

Executive Summary

Merck decided to halt lobbying efforts for state legislation requiring vaccination with its human papilloma virus vaccine Gardasil for school entry following discussions with third party stakeholders, including CDC's Advisory Committee on Immunization Practices and the American Academy of Pediatrics, the company said

You may also be interested in...



Vaccine Irony: COVID Complicates Review, Uptake Of New RSV Vaccines

COVID vaccines saved the world and then became a liability. US FDA vaccine advisors cited COVID experience as they urge agency to slow down on approval of new RSV vaccines, due to worries of declining public vaccine confidence and coadministration complications.

HIV Vaccine Trials: FDA Mulls Ethics Of Enrolling Teens; Is Phase II Too Soon?

The first approved HIV vaccine should be initially indicated for both adolescent and adult populations, but how and when to enroll adolescents in clinical trials is less straightforward, FDA's Pediatric Ethics Subcommittee determined at a June 9 meeting

HIV Vaccine Trials: FDA Mulls Ethics Of Enrolling Teens; Is Phase II Too Soon?

The first approved HIV vaccine should be initially indicated for both adolescent and adult populations, but how and when to enroll adolescents in clinical trials is less straightforward, FDA's Pediatric Ethics Subcommittee determined at a June 9 meeting

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel